Treatment of chronic hepatitis C: Present and future;Traitement de l'hepatite chronique virale C: Present et futur proche

Gastroenterologie Clinique et Biologique

Volumn 24, Issue 5, 2000, Pages 533-535

  Hezode, Christophe ^a   Dhumeaux, Daniel ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT;

DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; GENOTYPE; HEPATITIS C; HUMAN; SHORT SURVEY; TREATMENT OUTCOME; VIRUS LOAD; DRUG COMBINATION; REVIEW;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; RIBAVIRIN;

EID: 0034182348     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (21)

1. EASL International Consensus Conference on Hepatitis C. Consensus statement. J Hepatol 1999;30:956-61.
2. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
3. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk SG, Ideo G, et al. Randomized trial of interferon (2b plus ribavirin for 48 weeks or for 24 weeks versus interferon (2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
4. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an « à la carte » combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C ? Hepatology 2000;31:211-8.
5. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
6. Marcellin P, Hézode C, Castelnau C, Barange K, Couzigou P, Larrey D, et al. Randomized controlled trial of combination therapy with interferon (IFN) alfa-2a and ribavirin in patients with chronic hepatitis C who relapsed after interferon therapy (abstract). Hepatology 1999;30:192A.
7. Di Marco V, Almusio PL, Vaccaro A, Ferraro D, Parisi P, Cataldo MG, et al. Combined treatment of relapse of chronic hepatitis C with high-dose (2b interferon plus ribavirin for 6 or 12 months (abstract). Hepatology 1999;30:303A.
8. Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Hollander A, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis : analysis of individual patient data of six controlled trials. Gastroenterology 1999;117:408-13.
9. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-72.
10. Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, et al. Randomised, double-blind, placebo-controlled trial of interferon-alfa with and without amantadine as initial treatment for chronic hepatitis C (abstract). Hepatology 1999;30:200A.
11. Neumann AU, Lam NP, Dahari H, Grecht DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 1998;282:103-7.
12. Zeuzem S. Schmidt JM, Lee JH, Rüster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996;23:366-71.
13. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ, et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997;26:226-31.
14. Schiffman ML. Use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis 1999;19(Suppl 1) : 25-33.
15. Pimstone NR, Canio JB, Kao J, Kokosinski J, Saicheur T. High dose (780 MU : 52 weeks) interferon treatment for chronic hepatitis C : daily induction vs thrice weekly induction therapy (abstract). Hepatology 1999;30:264A.
16. Shiffman M, Pockros PJ, Reddy RK, Wright TL, Reindollar R, Fried MW, et al. A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon alpha-2a (PEG) vs standard interferon alpha-2a (IFN) for treatment of chronic hepatitis C (abstract). Gastroenterology 1999;116:1275A.
17. Trépo C, Lindsay K, Niederau C, Shiffman M, Gordon S, Hoefs J, et al. Pegylaled interferon alfa-2B (PBG-Intron) monotherapy is superior to interferon alfa-2B (Intron A) for the treatment of chronic hepatitis C (abstract). J Hepatol 2000;32(suppl 2) :29.
18. Zeuzem S, Feinman SW, Rasenack J, Heathcote Fu, Lai MY, Gane E, et al. Evaluation of the safety and efficacy of one-weekly PHG/interferon alfa-2A (Pegasus™) for chronic hepatitis C. A multinational randomized study (abstract). J Hepatol 2000;32(suppl 2):29.
19. Heathcote J, Shiffman ML, Cooksley G, Dusheiko GM, Lee SS, Balart L, et al. Multinational evaluation of the efficacy and safety of once-weekly peginterferon (-2a (PEG-IFN) in patients with chronic hepatitis C (CHC) with compensated cirrhosis (abstract). Hepatology 1999;30:316A.
20. Sulkowski M, Reindollar R, Yu J. Combination therapy with peginterferon (-2a (PEG-IFN) and ribavirin in the treatment of patients with chronic hepatitis C (CHC) : a phase II open-label study (abstract). Hepatology 1999;30:197A.
21. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-8.